Clinical trials: Excision of Kidney, open to volunteers
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract…
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma
- Trial name
- NCT05987241
- Testing
- Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography
- Where
- 505 sites in United States, Canada
- Volunteers
- 992 people
- Sponsor
- National Cancer Institute (NCI)
Congestion, RRT
Optimization of Fluid Balance Guided by Bioelectrical Impedance Analysis in Patients Undergoing Continuous Renal Replacement Therapy in Critical Care
In critical care, hemodynamic instability often requires volume expansion to restore tissue perfusion, increasing fluid balance and TBW, factors associated with higher mortality.
- Conditions
- Congestion, RRT, UF, Bio-impendance Analysis
- Trial name
- OBHIMER (NCT06799910)
- Testing
- continuous renal replacement therapy (CRRT), Free UF Prescription
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Urolithiasis, Calcium Oxalate, Kidney Stone
A Single-Center Clinical Study on the Efficacy and Safety of VISOR
Goal of this trial: To test a new tool called VISOR in adults (aged 18-80) with 1-3 cm kidney or ureter stones. We want to see: 1. If it's safe and works well 2.
- Trial name
- NCT07071948
- Testing
- Multifunctional Integrated Flexible Ureteroscope
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD)
DIALysis With EXpanded Solute Removal
The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is: 1) Does expanded hemodialysis reduce the risk of death from…
- Conditions
- Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD), Chronic Kidney Disease Requiring Chronic Dialysis, Pragmatic Randomized Controlled Trial
- Trial name
- DIALEX (NCT06660277)
- Testing
- Super High-Flux Dialyzer, High-Flux Dialyzer
- Where
- 3 sites in Canada
- Volunteers
- 4,800 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Acute Kidney Injury, Sepsis
Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury
The goal of this clinical trial is to learn if adding the iron-binding drug MEX-CD1 to dialysis fluid can help remove excess iron in adults with sepsis-associated acute kidney injury (AKI) requiring dialysis who are in the…
- Trial name
- IRON-IC (NCT07236463)
- Testing
- Continuous veino-veinous dialysis with iron-chelator supplemented dialysate
- Where
- 2 sites in France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma
This phase III trial compares the effect of pembrolizumab to active surveillance after a surgical procedure to completely or partially remove a kidney (nephrectomy) in improving time without disease in patients with non-clear…
- Conditions
- Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT07689240
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Volunteers
- 400 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Small Cell Lung Cancer (SCLC)
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
- Conditions
- Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin
- Trial name
- NCT07517198
- Testing
- EXS74539
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Renal Cell Carcinoma
Renal Adjuvant MultiPle Arm Randomised Trial
RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means).
- Trial name
- RAMPART (NCT03288532)
- Testing
- Durvalumab, Tremelimumab
- Where
- 35 sites in United Kingdom
- Volunteers
- 1,750 people
- Sponsor
- University College, London
Acute Respiratory Distress Syndrome, Acute Kidney Injury
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
PrismaLung+ is a sterile, single-use medical device aimed at performing partial removal of carbon dioxide (CO2) from the patient's venous blood via diffusion through a membrane.
- Trial name
- SPARE (NCT07326215)
- Testing
- PrismaLung+, Invasive Mechanical Ventilation
- Where
- 10 sites in China
- Volunteers
- 99 people
- Sponsor
- Vantive Health LLC
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery
This phase II trial compares the effect of adding a Live Biotherapeutic Product called CBM588 to pembrolizumab versus pembrolizumab alone in preventing return of disease (recurrence) after surgery for patients with renal cell…
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT07037004
- Testing
- Biospecimen Collection, Clostridium butyricum CBM588 Strain, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- City of Hope Medical Center
Non Muscle Invasive Bladder Cancer
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
This study is a prospective, randomized, multicenter clinical trial aiming to enroll 428 patients with non-muscle-invasive bladder cancer (NMIBC) from the Department of Urology at Jiangsu Provincial People's Hospital and its…
- Trial name
- NCT07036731
- Testing
- Urine biomarker -Guided without reTURBT
- Where
- China
- Volunteers
- 428 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Kidney Calculi, Kidney Stones
VISOR Versus PCNL for Treatment of 2-4cm Renal Stones
The goal of this clinical trial is to learn if the Vortex Intelligence Stone Optimized Removal (VISOR) works safely and effectively to treat kidney stones that are 2 to 4 centimeters in size in kidney.
- Trial name
- NCT07159503
- Testing
- Vortex Intelligence Stone Optimized Removal, Percutaneous Nephrolithotomy (PCNL)
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Chronic Kidney Diseases, Renal Failure Chronic
Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease
The goal of this observational study is to examine the interaction between the diuretic furosemide and certain toxins called protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD).
- Trial name
- FUROPBUT (NCT06750575)
- Testing
- Invasive measurements
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- UMC Utrecht
Acute Kidney Injury, Cardiac Surgery
Fluid-removal Guided by VeXUS Score With Usual Care in Patients With Acute Kidney Injury After Cardiac Surgery
Acute kidney injury affects more than 30% of patients after cardiac surgery, and is associated with an excess in mortality. There is a clinical continuum between acute kidney injury (transient if <48h, persistent if >48h), the…
- Conditions
- Acute Kidney Injury, Cardiac Surgery, Venous Congestion, Hemodynamic Stability
- Trial name
- VeXUS (NCT06251713)
- Testing
- VeXUS score guided fluid management strategy, Usual care
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Dialysis
Comparison of Hemodialysis Techniques in the Removal of Uremic Toxins in Chronic Renal Failure
In recent years, expanded hemodialysis has been the subject of studies, many of them done on small populations, with limited observation periods and not always unambiguous results.
- Trial name
- EMPIRE (NCT06794216)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Acute Kidney Injury, Continuous Renal Replacement Therapy (CRRT)
Ultrasound-Guided Microbubble Removal and Filter Lifespan During CRRT: A Pilot Crossover Study
What is this study about? This study is designed to evaluate whether ultrasound-guided removal of microbubbles during circuit priming in Continuous Renal Replacement Therapy (CRRT) can extend the filter lifespan for critically…
- Conditions
- Acute Kidney Injury, Continuous Renal Replacement Therapy (CRRT), Filter Clotting, Microbubbles
- Trial name
- NCT07005531
- Testing
- Ultrasound-Guided Microbubble Clearance During Circuit Priming
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
End Stage Renal Disease (ESRD), Chronic Kidney Disease on Hemodialysis
Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal
People with advanced kidney disease need dialysis to remove waste products from the blood. Some of these waste products, called uremic toxins, are small, while others are medium-sized and more difficult to remove.
- Conditions
- End Stage Renal Disease (ESRD), Chronic Kidney Disease on Hemodialysis, Renal Dialysis, Uremia; Chronic
- Trial name
- REMOV-HDx (NCT07348536)
- Testing
- Expanded Hemodialysis With Medium Cut-Off Membrane, High-Volume Online Hemodiafiltration
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Non Muscle Invasive Bladder Cancer
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection
The goal of this clinical trial is to evaluate the efficacy of using a urine biomarker test to guide the decision-making process regarding the necessity of reTURBT in NMIBC patients.
- Trial name
- NCT06287541
- Testing
- Urine biomarker -Guided without reTURBT
- Where
- China
- Volunteers
- 428 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pediatric Cancer, Neuroblastoma
Biomarkers of Resiliency In Childhood Cancer Surgery
This observational study is to better understand how children and their families recover after the stress of major surgery for cancer so that investigators can create ways to improve resilience during recovery.
- Conditions
- Pediatric Cancer, Neuroblastoma, Sarcoma, Wilms Tumor and Other Childhood Kidney Tumors
- Trial name
- BRICCS (NCT06674811)
- Testing
- Wearing Smartwatch, Patient Report Outcomes, Blood Draw
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Kidney Cancer
Resection or Ablation of Small Kidney Tumors
Ablative treatments are believed to have a lower rate of complications, shorter hospital stays, and fewer interventions with benign PAD compared to partial nephrectomies in small kidney cancer lesions.
- Trial name
- RESTART (NCT06278506)
- Testing
- Ablation, Surgery
- Where
- Sweden
- Volunteers
- 300 people
- Sponsor
- Karolinska University Hospital